ArticleJAMA oncology2026

Upadacitinib for Immune Checkpoint Inhibitor-Related Dermatitis: A Nonrandomized Clinical Trial.

Chengshui Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.